$PSTX
Poseida Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024027998 Filed on March 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $28.14M $25.00M $64.70M
YoY Change 172.09% 148.68% -50.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.798M $8.859M $37.44M
YoY Change -17.02% -5.43% -0.28%
% of Gross Profit
Research & Development $42.92M $42.05M $156.8M
YoY Change 12.8% 24.01% 2.53%
% of Gross Profit
Depreciation & Amortization $1.380M $1.438M $5.614M
YoY Change 4.23% 6.13% 8.55%
% of Gross Profit
Operating Expenses $52.72M $50.90M $194.2M
YoY Change 5.74% 17.64% 1.98%
Operating Profit -$24.58M -$129.5M
YoY Change -37.8% 116.03%
Interest Expense $2.253M -$2.267M $8.671M
YoY Change 11.09% 14.78% 36.12%
% of Operating Profit
Other Income/Expense, Net $2.556M $2.827M $14.85M
YoY Change -5.23% 30.28% 419.66%
Pretax Income -$24.27M -$25.35M -$123.3M
YoY Change -37.51% -23.25% 94.34%
Income Tax $0.00 $107.0K
% Of Pretax Income
Net Earnings -$24.30M -$25.35M -$123.4M
YoY Change -37.37% -23.92% 92.81%
Net Earnings / Revenue -86.35% -101.42% -190.72%
Basic Earnings Per Share -$0.25 -$1.37
Diluted Earnings Per Share -$0.25 -$0.26 -$1.37
COMMON SHARES
Basic Shares Outstanding 96.49M 95.62M 90.19M
Diluted Shares Outstanding 96.02M 90.19M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $198.6M $212.2M $212.2M
YoY Change -19.64% -24.88% -24.88%
Cash & Equivalents $53.30M $44.47M $44.47M
Short-Term Investments $145.3M $167.7M $167.7M
Other Short-Term Assets $6.059M $5.263M $5.263M
YoY Change 19.79% -24.62% -24.62%
Inventory
Prepaid Expenses
Receivables $12.03M $9.010M $9.010M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $216.7M $226.5M $226.5M
YoY Change -16.86% -24.14% -24.14%
LONG-TERM ASSETS
Property, Plant & Equipment $18.36M $19.06M $40.78M
YoY Change -16.96% -11.73% -12.62%
Goodwill $4.228M $4.228M
YoY Change 0.0% 0.0%
Intangibles $1.320M $1.320M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $1.081M $1.081M $1.081M
YoY Change 2.46% 2.46% 2.46%
Total Long-Term Assets $45.85M $47.41M $47.41M
YoY Change -13.37% -11.01% -11.01%
TOTAL ASSETS
Total Short-Term Assets $216.7M $226.5M $226.5M
Total Long-Term Assets $45.85M $47.41M $47.41M
Total Assets $262.6M $273.9M $273.9M
YoY Change -16.27% -22.16% -22.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.704M $3.267M $3.267M
YoY Change -15.5% 46.63% 46.63%
Accrued Expenses $27.81M $33.65M $33.65M
YoY Change 36.22% 19.98% 19.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $84.76M $71.32M $71.32M
YoY Change 74.09% 32.35% 32.35%
LONG-TERM LIABILITIES
Long-Term Debt $58.69M $58.59M $58.59M
YoY Change 0.63% 0.58% 0.58%
Other Long-Term Liabilities $2.754M $2.614M $40.28M
YoY Change 22.67% 25.01% -22.62%
Total Long-Term Liabilities $61.45M $61.20M $98.87M
YoY Change 1.45% 1.43% -10.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $84.76M $71.32M $71.32M
Total Long-Term Liabilities $61.45M $61.20M $98.87M
Total Liabilities $178.0M $170.2M $170.2M
YoY Change 14.05% 3.62% 3.62%
SHAREHOLDERS EQUITY
Retained Earnings -$618.6M -$594.3M
YoY Change 21.37% 26.21%
Common Stock $703.2M $697.9M
YoY Change 5.39% 5.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.59M $103.7M $103.7M
YoY Change
Total Liabilities & Shareholders Equity $262.6M $273.9M $273.9M
YoY Change -16.27% -22.16% -22.16%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$24.30M -$25.35M -$123.4M
YoY Change -37.37% -23.92% 92.81%
Depreciation, Depletion And Amortization $1.380M $1.438M $5.614M
YoY Change 4.23% 6.13% 8.55%
Cash From Operating Activities -$15.10M -$28.74M -$92.20M
YoY Change -60.26% -1296.17% 244.03%
INVESTING ACTIVITIES
Capital Expenditures $130.0K $309.0K $3.066M
YoY Change -83.42% 18.85% -21.87%
Acquisitions
YoY Change
Other Investing Activities $24.13M $48.02M $42.20M
YoY Change -764.64% -156.08% -121.16%
Cash From Investing Activities $24.00M $47.71M $39.13M
YoY Change -643.67% -155.55% -119.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $928.0K
YoY Change -98.77%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -43.00K -3.000K 16.13M
YoY Change -103.63% -105.17% -84.66%
NET CHANGE
Cash From Operating Activities -15.10M -28.74M -92.20M
Cash From Investing Activities 24.00M 47.71M 39.13M
Cash From Financing Activities -43.00K -3.000K 16.13M
Net Change In Cash 8.825M 18.97M -36.91M
YoY Change -121.4% -122.74% -70.46%
FREE CASH FLOW
Cash From Operating Activities -$15.10M -$28.74M -$92.20M
Capital Expenditures $130.0K $309.0K $3.066M
Free Cash Flow -$15.23M -$29.05M -$95.27M
YoY Change -60.73% -1455.72% 210.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001661460
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2022 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39376
CY2023 dei Entity Registrant Name
EntityRegistrantName
POSEIDA THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2846548
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
9390 Towne Centre Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
779-3100
CY2023 dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
PSTX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
122800000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96489127
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44472000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81378000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
167730000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
201115000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9010000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9088000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5263000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6982000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
226475000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
298563000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19055000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21586000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21726000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25085000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2023Q4 us-gaap Goodwill
Goodwill
4228000
CY2022Q4 us-gaap Goodwill
Goodwill
4228000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1081000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1055000
CY2023Q4 us-gaap Assets
Assets
273885000
CY2022Q4 us-gaap Assets
Assets
351837000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3267000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2228000
CY2023Q4 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
31092000
CY2022Q4 pstx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
26068000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5951000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5866000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31008000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19723000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71318000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53885000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
58590000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
58250000
CY2022Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
3992000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16780000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
21333000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20882000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24636000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2614000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2146000
CY2023Q4 us-gaap Liabilities
Liabilities
170184000
CY2022Q4 us-gaap Liabilities
Liabilities
164242000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95636553
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95636553
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85964161
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85964161
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
697856000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
658596000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
126000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-149000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594291000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470861000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
103701000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
187595000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
273885000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351837000
CY2023 us-gaap Revenues
Revenues
64703000
CY2022 us-gaap Revenues
Revenues
130492000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156772000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152899000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37435000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-808000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-844000
CY2023 pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
-8385000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37539000
CY2023 us-gaap Operating Expenses
OperatingExpenses
194207000
CY2022 us-gaap Operating Expenses
OperatingExpenses
190438000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-129504000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-59946000
CY2023 us-gaap Interest Expense
InterestExpense
8671000
CY2022 us-gaap Interest Expense
InterestExpense
6370000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14852000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2858000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123323000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63458000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
107000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-123430000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64002000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
275000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123155000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64151000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90185096
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90185096
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71953703
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71953703
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1310000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18926000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-149000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64002000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
187595000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
782000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23134000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
275000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-123430000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
103701000
CY2023 us-gaap Profit Loss
ProfitLoss
-123430000
CY2022 us-gaap Profit Loss
ProfitLoss
-64002000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5614000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5172000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-348000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
23134000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
18926000
CY2023 pstx Write Off Of Deferred Grant Liability
WriteOffOfDeferredGrantLiability
-3992000
CY2022 pstx Amortization Accretion On Investment Securities Net
AmortizationAccretionOnInvestmentSecuritiesNet
-1775000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-77000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9088000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1565000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-499000
CY2023 pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3359000
CY2022 pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
4605000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
25000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-605000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1038000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6748000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
5004000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1399000
CY2023 pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3669000
CY2022 pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4852000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6732000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
27295000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92167000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26772000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3066000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3924000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
237800000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
294422000
CY2023 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
280000000
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
95000000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39134000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-203334000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1276000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1310000
CY2023 pstx Payment Of Taxes Related To Net Share Settlement Of Equity Awards
PaymentOfTaxesRelatedToNetShareSettlementOfEquityAwards
494000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
928000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14417000
CY2022 pstx Proceeds From Issuance Of Public Offering
ProceedsFromIssuanceOfPublicOffering
75299000
CY2022 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
30000000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1450000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16127000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105159000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36906000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-124947000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81378000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206325000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81378000
CY2023 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
20000
CY2022 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1144000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4425000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
7796000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5138000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-123400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-64000000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92200000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26800000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594300000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
212200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to revenue, accrued expenses, research and development expenses, stock-based compensation expense and deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 pstx Number Of Revenue Performance Obligation
NumberOfRevenuePerformanceObligation
1
CY2023 pstx Number Of Reportable Segment
NumberOfReportableSegment
1
CY2023 pstx Number Of Customer
NumberOfCustomer
2
CY2023 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days.
CY2023 pstx Costs Incurred To Obtain Contracts
CostsIncurredToObtainContracts
0
CY2023 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days.
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
1556000
CY2022Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
2465000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
995000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1507000
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
506000
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
492000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2206000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2518000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5263000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6982000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37864000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35062000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18809000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13476000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19055000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21586000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5600000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5200000
CY2023Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
14621000
CY2022Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
10908000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13076000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11271000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3395000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3889000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
31092000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
26068000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
205194000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
158000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
32000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
205320000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
264319000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
162000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
264170000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2023 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2022 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q3 pstx Non Refundable Upfront Payment
NonRefundableUpfrontPayment
35600000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13762000
CY2022 pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
157786000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-130492000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41056000
CY2023 pstx Contract With Customer Liability Amounts Received Invoiced
ContractWithCustomerLiabilityAmountsReceivedInvoiced
71435000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-64703000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47788000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1400000
CY2023Q4 pstx Debt Instrument Final Payment Fee Accrued
DebtInstrumentFinalPaymentFeeAccrued
2600000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2023Q4 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2023Q4 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2023Q4 pstx Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
14909912
CY2023Q4 pstx Restricted Stock Units Issued And Outstanding
RestrictedStockUnitsIssuedAndOutstanding
4555099
CY2023Q4 pstx Authorized For Future Options And Award Grants
AuthorizedForFutureOptionsAndAwardGrants
4332980
CY2023Q4 pstx Authorized For Future Issuance Under Employee Stock Purchase Plan
AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlan
1773794
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25571785
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11861881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4054949
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.69
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
37166
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.65
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
969752
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.41
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14909912
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.84
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M19D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1680000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14909912
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.84
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M19D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1680000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8003272
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.01
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M2D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
840000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.4
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
22300000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
22100000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
24100000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
300000
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
300000
CY2019Q3 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-06-26
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0216
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8259
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8494
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23134000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18926000
CY2018Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2019-04-01
CY2018Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2019Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-07-29
CY2019Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2019Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2022Q4 pstx One Time Cash Security Deposit
OneTimeCashSecurityDeposit
100000
CY2023Q4 pstx One Time Cash Security Deposit
OneTimeCashSecurityDeposit
100000
CY2023Q4 us-gaap Area Of Land
AreaOfLand
110000
CY2023 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease agreements include two options to extend the term for a period of 5 years each.
CY2023 pstx Lessee Operating Lease Number Of Options To Extend Term
LesseeOperatingLeaseNumberOfOptionsToExtendTerm
2
CY2023 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
5800000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
7000000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
6300000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0892
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6188000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6374000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5107000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5260000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5418000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5581000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33928000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7095000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26833000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5951000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20882000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-123323000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-63458000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123323000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63458000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91285000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
89300000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
48119000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
38674000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
39341000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
51000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
456000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
56000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
88000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
107000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
544000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
107000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
25898000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
13326000
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
12938000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
9026000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
6856000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2842000
CY2023 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
2970000
CY2022 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
2209000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3279000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3106000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
224000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
171000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
39326000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20252000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
107000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
544000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
23370000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
9965000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2584000
CY2023Q4 pstx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
7514000
CY2022Q4 pstx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
8468000
CY2023Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
5136000
CY2022Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1252000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3436000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2910000
CY2022Q4 pstx Deferred Tax Assets Grant Income
DeferredTaxAssetsGrantIncome
1108000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4910000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3612000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
209706000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
171278000
CY2023Q4 pstx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6084000
CY2022Q4 pstx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6965000
CY2023Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
2003000
CY2022Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1948000
CY2023Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
370000
CY2022Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
366000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8457000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9279000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
201304000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
162054000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
201300000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
162100000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15300000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11805000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9494000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3091000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2403000
CY2023 pstx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
383000
CY2022 pstx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-92000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15279000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11805000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15300000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1900000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1500000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19830039
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14642690

Files In Submission

Name View Source Status
0000950170-24-027998-index-headers.html Edgar Link pending
0000950170-24-027998-index.html Edgar Link pending
0000950170-24-027998.txt Edgar Link pending
0000950170-24-027998-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img93556996_0.jpg Edgar Link pending
img93556996_1.jpg Edgar Link pending
img93556996_10.jpg Edgar Link pending
img93556996_11.jpg Edgar Link pending
img93556996_12.jpg Edgar Link pending
img93556996_13.jpg Edgar Link pending
img93556996_14.jpg Edgar Link pending
img93556996_15.jpg Edgar Link pending
img93556996_16.jpg Edgar Link pending
img93556996_17.jpg Edgar Link pending
img93556996_18.jpg Edgar Link pending
img93556996_19.jpg Edgar Link pending
img93556996_2.jpg Edgar Link pending
img93556996_20.jpg Edgar Link pending
img93556996_21.jpg Edgar Link pending
img93556996_22.jpg Edgar Link pending
img93556996_23.jpg Edgar Link pending
img93556996_24.jpg Edgar Link pending
img93556996_25.jpg Edgar Link pending
img93556996_26.jpg Edgar Link pending
img93556996_3.jpg Edgar Link pending
img93556996_4.jpg Edgar Link pending
img93556996_5.jpg Edgar Link pending
img93556996_6.jpg Edgar Link pending
img93556996_7.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img93556996_8.jpg Edgar Link pending
img93556996_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pstx-20231231.htm Edgar Link pending
pstx-20231231.xsd Edgar Link pending
pstx-ex10_30.htm Edgar Link pending
pstx-ex23_1.htm Edgar Link pending
pstx-ex23_2.htm Edgar Link pending
pstx-ex31_1.htm Edgar Link pending
pstx-ex31_2.htm Edgar Link pending
pstx-ex32_1.htm Edgar Link pending
pstx-ex32_2.htm Edgar Link pending
pstx-ex97_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pstx-20231231_htm.xml Edgar Link completed